Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | GAA | P10253 | 7/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 1.00 |
| ▸ | IDO1 | P14902 | 1/20 | 1.00 |
| ▸ | NOX1 | Q9Y5S8 | 10/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | SNCA | P37840 | 3/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
| ▸ | BCHE | P06276 | 2/20 | 0.65 |
| ▸ | ACHE | P22303 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12396548 | 0.90 | GAA (0.81) | MAPTGAAL3MBTL1IDO1NOX1 | |
| SCHEMBL7888523 | 0.89 | MAPT (0.79) | MAPTGAAL3MBTL1IDO1NOX1 | |
| Phenothiazine SCHEMBL27881746 | 0.84 | NOX1 (0.77) | MAPTGAAL3MBTL1IDO1NOX1 | |
| Phenothiazine SCHEMBL29352248 | 0.81 | NOX1 (1.00) | MAPTGAAL3MBTL1IDO1NOX1 | |
| Phenothiazine SCHEMBL6315328 | 0.81 | NOX1 (1.00) | MAPTGAAL3MBTL1IDO1NOX1 | |
| Phenothiazine SCHEMBL29349533 | 0.81 | NOX1 (1.00) | MAPTGAAL3MBTL1IDO1NOX1 | |
| Phenothiazine SCHEMBL2504207 | 0.81 | NOX1 (1.00) | MAPTGAAL3MBTL1IDO1NOX1 | |
| Phenothiazine SCHEMBL9114 | 0.81 | NOX1 (1.00) | MAPTGAAL3MBTL1IDO1NOX1 | |
| Phenothiazine SCHEMBL30330193 | 0.80 | NOX1 (0.71) | MAPTGAAL3MBTL1IDO1NOX1 | |
| Phenothiazine SCHEMBL28577557 | 0.80 | NOX1 (0.71) | MAPTGAAL3MBTL1IDO1NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910379-B1 | CASPASE INHIBITOR PRODRUGS | VERTEX PHARMA (US) | 2011-10-19 | — | — | EP | claimed |
| US-20110144074-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-16 | — | — | US | claimed |
| US-7879891-B2 | such as (S)-Carbazole-9-carboxylic acid 1-(3a-fluoromethyl-5-oxo-3a,5,6,6a-tetrahydro-furo[3,2-d]oxazol-2-yl)-2-methyl-propyl ester, used for the treatment of diseases related to inflammatory or degenerative conditions | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | claimed |
| US-20090215736-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2009-08-27 | — | — | US | claimed |
| US-20080311051-A1 | Caspase-2 Inhibitors And Their Biological Applications | THERAPTOSIS SA (FR) | 2008-12-18 | — | — | US | claimed |
| US-7442790-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2008-10-28 | — | — | US | claimed |
| EP-1923386-A2 | Carbamate caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2008-05-21 | — | — | EP | claimed |
| EP-1268425-B1 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2008-01-23 | — | — | EP | claimed |
| US-20080015172-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | claimed |
| US-20070155718-A1 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-05 | — | — | US | claimed |
| EP-1740614-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | Theraptosis S.A. (FR) | 2007-01-10 | — | — | EP | claimed |
| US-7074782-B2 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-07-11 | — | — | US | claimed |
| WO-2005105829-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | THERAPTOSIS S.A. (FR) | 2005-11-10 | — | — | WO | claimed |
| US-20040053920-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-03-18 | — | — | US | claimed |
| EP-1392289-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030092703-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| EP-1268425-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2003-01-02 | — | — | EP | claimed |
| WO-2002094263-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-28 | — | — | WO | claimed |
| US-20020028803-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-03-07 | — | — | US | claimed |
| WO-2001072707-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-10-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028803-A1 | Carbamate caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | MAPT 4419/4885GAA 3111/4885L3MBTL1 393/4885 |
| US-20070155718-A1 | Caspase inhibitor prodrugs | CASP1, CASP5, CASP2 | MAPT 1365/4885GAA 800/4885L3MBTL1 1221/4885 |
| US-20080311051-A1 | Caspase-2 Inhibitors And Their Biological Applications | CASP1, CASP2, CASP9 | MAPT 3990/4885GAA 1060/4885L3MBTL1 90/4885 |
| US-20080015172-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP2, CASP9 | MAPT 4560/4885GAA 4138/4885L3MBTL1 275/4885 |
| US-20110144074-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP2, CASP9 | MAPT 4550/4885GAA 4099/4885L3MBTL1 330/4885 |
| US-20040053920-A1 | Carbamate caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | MAPT 4419/4885GAA 3111/4885L3MBTL1 393/4885 |
| US-20090215736-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP2, CASP9 | MAPT 4550/4885GAA 4099/4885L3MBTL1 330/4885 |
| US-20030092703-A1 | Caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | MAPT 4629/4885GAA 3199/4885L3MBTL1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.